Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab alone versus pembrolizumab plus chemotherapy in first-line NSCLC
2019-002743-26Phase 3Active
- Sponsor
- Paulien van Deutekom Foundation
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Paulien van Deutekom Foundation. Primary endpoint: Overall response rate at week 6. Started Feb 2020; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-002743-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002743-26.